These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27769352)

  • 21. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines.
    Yan Z; Lyu X; Lin D; Wu G; Gong Y; Ren X; Xiao J; Lou J; Huang H; Chen Y; Zhao Y
    Eur J Med Chem; 2023 Jun; 254():115381. PubMed ID: 37084596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
    Wu SY; Lai HT; Sanjib Banerjee N; Ma Z; Santana JF; Wei S; Liu X; Zhang M; Zhan J; Chen H; Posner B; Chen Y; Price DH; Chow LT; Zhou J; Chiang CM
    Mol Cell; 2024 Jan; 84(2):202-220.e15. PubMed ID: 38103559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice.
    Benito E; Ramachandran B; Schroeder H; Schmidt G; Urbanke H; Burkhardt S; Capece V; Dean C; Fischer A
    Transl Psychiatry; 2017 Sep; 7(9):e1239. PubMed ID: 28949335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression.
    Wu SY; Nin DS; Lee AY; Simanski S; Kodadek T; Chiang CM
    Cell Rep; 2016 Aug; 16(6):1733-1748. PubMed ID: 27477287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
    Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
    ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromodomains as therapeutic targets in cancer.
    Barbieri I; Cannizzaro E; Dawson MA
    Brief Funct Genomics; 2013 May; 12(3):219-30. PubMed ID: 23543289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4.
    Ren K; Zhang W; Chen X; Ma Y; Dai Y; Fan Y; Hou Y; Tan RX; Li E
    PLoS Pathog; 2016 Oct; 12(10):e1005950. PubMed ID: 27764245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRD4: New hope in the battle against glioblastoma.
    Duan W; Yu M; Chen J
    Pharmacol Res; 2023 May; 191():106767. PubMed ID: 37061146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.
    Guan X; Cheryala N; Karim RM; Chan A; Berndt N; Qi J; Georg GI; Schönbrunn E
    J Med Chem; 2022 Aug; 65(15):10441-10458. PubMed ID: 35867655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins.
    Malvezzi F; Stubbs CJ; Jowitt TA; Dale IL; Guo X; DeGnore JP; Degliesposti G; Skehel JM; Bannister AJ; McAlister MS
    Commun Biol; 2021 Nov; 4(1):1273. PubMed ID: 34754068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of the Transcriptome and Genome-Wide Landscape of BRD2 and BRD4 Binding Motifs Identifies Key Superenhancer Genes and Reveals the Mechanism of Bet Inhibitor Action in Rheumatoid Arthritis Synovial Fibroblasts.
    Krishna V; Yin X; Song Q; Walsh A; Pocalyko D; Bachman K; Anderson I; Madakamutil L; Nagpal S
    J Immunol; 2021 Jan; 206(2):422-431. PubMed ID: 33288543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
    Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
    Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.